The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...
In its fourth-quarter earnings report, Moderna’s revenue was down substantially from 2023. Separately, media reports reveal ...
The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.
The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...
Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...
The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...
Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...
Robert F. Kennedy Jr.—whose history of anti-vaccine rhetoric has had the healthcare and biopharma industries on edge—was ...
Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.
Encoded’s layoffs will mostly affect its technology and early-stage research and development functions. The move is expected ...
In this episode, presented by the Genscript Biotech Global Forum 2025, BioSpace's Head of Insights Lori Ellis and Tom ...
The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results